Management of acute toxoplasmosis differs significantly based on the patient's immune status. This protocol addresses the specific scenario of a non-immunodeficient adult presenting with the lymphadenopathic form of the disease.
In immunocompetent adults, lymphadenopathic toxoplasmosis is typically self-limited and treatment is rarely indicated. The key clinical decision is identifying the subset of patients whose course warrants intervention — those with visceral involvement or symptoms that are severe or persistent.
Antiparasitic therapy becomes relevant when the disease does not follow the expected self-limited course. The full structured protocol — covering precise indications, therapeutic selection, and management guidance — is accessible below.
Treatment of immunocompetent adults with lymphadenopathic toxoplasmosis is rarely indicated; this form of the disease is usually self-limited.
If visceral disease is clinically evident or symptoms are severe or persistent, treatment may be indicated for 2 to 4 weeks.
View source ↗